MedTrace Logo

Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis

NCT05488327 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-08-04

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of lenalidomide in the treatment of patients with active cutaneous DM.

Conditions

  • Dermatomyositis

Interventions

DRUG

Lenalidomide

All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.

Sponsors & Collaborators

  • Jiangxi Provincial People's Hopital

    lead OTHER

Principal Investigators

  • Lihua Duan, MD · Jiangxi Provincial People's Hopital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-08-01
Completion
2023-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05488327 on ClinicalTrials.gov